CureVac Withdraws COVID-19 Vaccine Application in EU
CureVac has withdrawn its EU application for its messenger RNA-based COVID-19 vaccine candidate, CVnCoV, and says it will instead focus on developing a second-generation shot with GlaxoSmithKline (GSK).
CureVac explained that the earliest window for authorization of CVnCoV would have been during the second quarter of 2022, at which point the drugmaker expects to have its new vaccine candidate in late-stage trials.
CureVac and GSK anticipate securing regulatory approval of the second-generation mRNA vaccine sometime next year.
The German company said its existing advance supply deal for CVnCoV with the European Commission will be terminated.